Subscribe
crystal light / Shutterstock.com
27 August 2024NewsAmericasLiz Hockley

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Biopharma firm sues CSPC for allegedly infringing Onivyde patent issued in August | Suit follows complaint in April asserting eight patents against Conjupro’s product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.

More on this story

Americas
FDA prevails in Ipsen dispute over ‘biologic’ definition
30 July 2024   Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks